|
|
 |
|
Viewing report
|
|
|
|
Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review
GlobalData, Aug 2011, Pages: 43
Pharmacyclics, Inc. (PCYC) - Financial and Strategic SWOT Analysis Review
Summary
Pharmacyclics, Inc. (Pharmacyclics) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of innovative small-molecule drugs for the treatment of immune mediated disease and cancer. With synthetic small molecules as its pharmaceutical agents, the company targets key biochemical pathways in diseased cells. Its deep and broad pipeline includes four proprietary drug candidates under clinical development and and several preclinical molecules in lead optimization. The company entered into a global strategic alliance with Servier, for the research, development, and commercialization of Pharmacyclics' PCI-24781, an orally active, small molecule inhibitor of Pan HDAC enzymes, for the treatment of solid tumors and hematologic malignancies. Pharmacyclics is headquartered at Sunnyvale, California, the US.
Pharmacyclics, Inc. Key Recent Developments…
Jun 06, 2011 Pharmacyclics Reports Recent Developments From Clinical Studies Of Btk Inhibitor PCI-32765
May 04, 2011 Pharmacyclics Reports Net Loss Of $9.2m For Q3 Fiscal 2010
Feb 04, 2011 Pharmacyclics Reports Net Loss Of $7.5 Million For Q2 Fiscal 2011
Nov 08, 2010 Pharmacyclics Reports Net loss Of $7.5 Million For Q1 Fiscal 2011
Sep 13, 2010 Pharmacyclics Reports Net Loss Of $6.8 Million For Q4 Fiscal 2010
This comprehensive SWOT profile of Pharmacyclics, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Pharmacyclics, Inc. - Product Pipeline Review - H2 2011
Pharmacyclics, Inc. - Product Pipeline Review - Q4 2010
Pharmacyclics, Inc. - Product Pipeline Review - Q4 2010
Pharmacyclics, Inc. - Product Pipeline Review - Q1 2011
Thallion Pharmaceuticals Inc. (TLN) - Financial and Strategic SWOT Analysis Review
ArQule, Inc. (ARQL) - Financial and Strategic SWOT Analysis Review
Array BioPharma Inc. (ARRY) - Financial and Strategic SWOT Analysis Review
BioCryst Pharmaceuticals, Inc. (BCRX) - Financial and Strategic SWOT Analysis Review
MethylGene Inc (MYG) - Financial and Strategic SWOT Analysis Review
Rigel Pharmaceuticals, Inc. (RIGL) - Financial and Strategic SWOT Analysis Review
|
|
|
|
